Screening for prostate cancer: An updated Cochrane systematic review

BJU International

Volumn 107, Issue 6, 2011, Pages 882-891

  Ilic, Dragan ^a   O'Connor, Denise ^a   Green, Sally ^a   Wilt, Timothy J ^b,c  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Prostate cancer; Screening; Systematic review

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLEEDING; CANCER MORTALITY; CANCER SCREENING; COCHRANE LIBRARY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; HUMAN; INFECTION; LIFE EXPECTANCY; META ANALYSIS (TOPIC); PAIN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 79952604359     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10032.x     Document Type: Review

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9 (Pubitemid 14026148)
3. Holman CD, Wisniewski ZS, Semmens JB, Rouse IL, Bass AJ. Mortality and prostate cancer risk in 19598 men after surgery for benign prostatic hyperplasia. BJU Int 1999; 84: 37-42 (Pubitemid 29346772)
4. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev 2006; 3: CD004720
5. Gambert SR. Screening for prostate cancer. Int Urol Nephrol 2001; 33: 249-57 (Pubitemid 34575372)
6. Holmstrom B, Johansson M, Bergh A, Stenman UH, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ 2009; 339: b3537
7. Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9
8. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
9. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev 2010; issue 11, CD004720
10. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2008
11. The Nordic Cochrane Centre. Review Manager (RevMan) 5.0. The Cochrane Collaboration
12. Hugosson J, Carlsson S, Aus G et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-32
13. Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 2004; 46: 717-24
14. Varenhorst E, Carlsson P, Capik E, Lofman O, Pedersen K. Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. Acta Oncol 1992; 31: 815-21 (Pubitemid 23089752)
15. Prorok PC, Andriole GL, Bresalier RS et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Control Clin Trials 2000; 21 (Suppl.): 273S-309S
16. Labrie F, Candas B, Cusan L et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311-8
17. Labrie F, Candas B, Dupont A et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83-91
18. Labrie F, Cusan L, Gomez J, Levesque J, Candas B. Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening. Aging Male 1999; 2: 33-43 (Pubitemid 29305451)
19. Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. Dihydrotestosterone levels and survival in screening-detected prostate cancer: a 15-yr follow-up study. Eur Urol 2007; 53: 106-11
20. Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. 15-Year follow up of a population based prostate cancer screening study. J Urol 2009; 181: 1615-21
21. Schroder FH, Damhuis RA, Kirkels WJ et al. European randomized study of screening for prostate cancer - the Rotterdam pilot studies. Int J Cancer 1996; 65: 145-51 (Pubitemid 26048912)
22. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schroder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60: 826-30 (Pubitemid 35300348)
23. Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol 2009; 6: 87-95
24. Johansson E, Bill-Axelson A, Holmberg L, Onelov E, Johansson JE, Steineck G. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol 2009; 55: 422-30
25. Bill-Axelson A, Holmber L, Filen F et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144-54
26. Sakr WA, Grignon DJ, Haas GP, Heilbrum LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996; 30: 138-44 (Pubitemid 26285528)
27. Draisma G, Boer R, Osst SJ et al. Lead time and over detection due to prostate specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78 (Pubitemid 36833878)
28. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009; 302: 1685-92
29. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001; 19: 1619-28 (Pubitemid 32230861)
30. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-84 (Pubitemid 40638368)
31. O'Connor AM, Bennett CL, Stacey D et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2009; 3: CD001431